Iloperidone is a benzisoxazole phenylethanone second-generation antipsychotic used to treat schizophrenia. Iloperidone inhibits D2 receptors and 5-HT2A receptors, resulting in fewer extrapyramidal symptoms than first-generation antipsychotics. This compound may inhibit K+ repolarization (hERG) channels, prolonging the QT interval and inducing ventricular tachyarrhythmia.
| Cas No. | 133454-47-4 |
|---|---|
| Purity | ≥99% |
| Formula | C24H27FN2O4 |
| Formula Wt. | 426.48 |
| IUPAC Name | 1-[4-[3-[4-(6-fluoro-1, 2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Dargani NV, Malhotra AK. Safety profile of iloperidone in the treatment of schizophrenia. Expert Opin Drug Saf. 2013 Nov 11. [Epub ahead of print]. PMID: 24206391.
Achalia R, Andrade C. Ventricular premature contractions associated with iloperidone. Indian J Psychiatry. 2013 Apr;55(2):195-6. PMID: 23825860.
Marino J, Caballero J. Iloperidone for the treatment of schizophrenia. Ann Pharmacother. 2010 May;44(5):863-70. PMID: 20388862.
